Chimerix (NASDAQ:CMRX) Earns Neutral Rating from HC Wainwright

HC Wainwright reissued their neutral rating on shares of Chimerix (NASDAQ:CMRX) in a research note released on Wednesday morning,Benzinga reports. They currently have a $8.55 target price on the biopharmaceutical company’s stock, down from their prior target price of $11.00.

Separately, Wedbush restated an “outperform” rating and set a $7.00 price target (up from $6.00) on shares of Chimerix in a research note on Tuesday, February 18th.

Chimerix Stock Up 70.6 %

Shares of CMRX opened at $8.46 on Wednesday. Chimerix has a 12-month low of $0.75 and a 12-month high of $8.47. The firm has a market capitalization of $760.86 million, a price-to-earnings ratio of -9.00 and a beta of 0.32. The stock’s 50-day moving average price is $4.04 and its 200 day moving average price is $2.17.

Insider Buying and Selling at Chimerix

In other Chimerix news, CEO Michael T. Andriole sold 7,370 shares of Chimerix stock in a transaction that occurred on Thursday, February 13th. The stock was sold at an average price of $4.52, for a total transaction of $33,312.40. Following the sale, the chief executive officer now directly owns 609,603 shares of the company’s stock, valued at approximately $2,755,405.56. The trade was a 1.19 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Over the last ninety days, insiders have sold 20,760 shares of company stock valued at $91,175. 13.10% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Chimerix

Institutional investors have recently added to or reduced their stakes in the stock. Bender Robert & Associates acquired a new stake in Chimerix during the fourth quarter valued at approximately $37,000. Susquehanna Fundamental Investments LLC acquired a new position in shares of Chimerix in the 4th quarter worth approximately $59,000. Jane Street Group LLC acquired a new position in shares of Chimerix in the 4th quarter worth approximately $62,000. Diadema Partners LP acquired a new position in shares of Chimerix in the 4th quarter worth approximately $101,000. Finally, Squarepoint Ops LLC acquired a new position in shares of Chimerix in the 4th quarter worth approximately $130,000. 45.42% of the stock is owned by institutional investors and hedge funds.

About Chimerix

Chimerix, Inc, a biopharmaceutical company, develops medicines to improve and extend the lives of patients facing deadly diseases. Its pipeline products include ONC201 a program that is in Phase 3 clinical trial for treating patients with H3 K27M-mutant diffuse glioma, as well as in Phase 2 clinical trial for the treatment of rare neuroendocrine tumors; and ONC206, an imipridone, Dopamine Receptor D2 (DRD2) antagonist, and caseinolytic protease P (ClpP) agonist, which is in Phase 1 clinical trial for adult and pediatric patients with primary central nervous system tumors.